Bellerophon Therapeutics, Inc.
CIK 0001600132
Revenue (TTM)
—
Q3 Nov 2023
Net Income (TTM)
−$9.31M
−11.7% YoY
Q3 Nov 2023
EPS Diluted (TTM)
−$0.84
−11.2% YoY
Q3 Nov 2023
Gross Margin
—
Q3 Nov 2023
Operating Margin
—
Q3 Nov 2023
Net Margin
—
Q3 Nov 2023
Free Cash Flow (TTM)
−$13.69M
Q3 Nov 2023
Cash
$4.38M
Q3 Nov 2023
Total Debt
—
Q3 Nov 2023
Shares Outstanding
12.23M sh
Q3 Nov 2023
Revenue & Net Income
EPS (Diluted)
Cash Flow
Revenue Growth (YoY)
No data available for this metric.